NCT02007252

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study of Subcutaneous ACZ885 for the Treatment of Abdominal Aortic Aneurysm

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 65 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aortic aneurysms. The design of this study addressed the primary objective of evaluating the change in aneurysmal size in subjects with AAA as a result of treatment with ACZ885.

Conditions

• Abdominal Aortic Aneurysm (AAA)

Interventions

Type	Name	Description
DRUG	ACZ885	ACZ885 150 mg liquid pre-filled syringes were administered s.c..
DRUG	Placebo	Matching placebo liquid pre-filled syringes were administered s.c..

Timeline

• Start date: 2013-12-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2013-12-10
• Last updated: 2021-01-05
• Results posted: 2016-11-21

Locations

9 sites across 5 countries: United States, Denmark, Netherlands, Sweden, United Kingdom